Faculty

Jonathan J Miner, M.D., Ph.D.

Associate Professor of Medicine (Rheumatology)

Department: Medicine

Graduate Group Affiliations

Contact information

522B Johnson Pavilion
3610 Hamilton Walk
Philadelphia, PA 19104

Office: 215-573-4109

Email:
jonathan.miner@pennmedicine.upenn.edu

Publications

Search PubMed for articles

Education:
B.A. (Russian)
BYU, 2002.
B.S. (Zoology)
BYU, 2002.
Ph.D. (Biochemistry and Molecular Biology)
University of Oklahoma, 2008.
M.D. (Medicine)
University of Oklahoma, 2010.

Links
Search PubMed for articles
Miner Lab Website
RVCL Research Center

Permanent link

> Perelman School of Medicine > Faculty > Details

Description of Clinical Expertise

Dr. Miner sees patients with rare autoinflammatory diseases and vasculopathies caused by single-gene mutations. This includes RVCL (also known as RVCL-S), AGS, SAVI, COPA syndrome, and others. Dr. Miner chairs the Gene Therapy and Vaccines Ph.D. program at Penn, and his research laboratory studies fundamental immunology, mechanisms of genetic disease, and develops custom medicines for patients with rare genetic diseases.

Description of Research Expertise

Dr. Jonathan Miner, MD, PhD, is an Associate Professor of Medicine at the University of Pennsylvania Perelman School of Medicine. He specializes in inherited autoimmune and autoinflammatory diseases resulting from mutations in genes that regulate immune responses to DNA and RNA. A member of the American Society for Clinical Investigation (ASCI), Dr. Miner has received numerous accolades, including the Ann Palmenberg Award from the American Society for Virology. He also chairs the Gene Therapy and Vaccines (GTV) Ph.D. program at Penn. Dr. Miner's research has been published in top journals such as Nature Medicine, Science Translational Medicine, and Cell. Dr. Miner also provides care for rare disease patients worldwide, and his team has developed animal models that feature human disease-causing mutations in a wide variety of innate immune genes including STING, TREX1, RELA, STAT1, and IFIH1. These models are utilized to elucidate fundamental biology, to demonstrate underlying mechanisms of disease, and to advance the development of personalized therapies for patients.

Selected Publications

Poddar S, Chauvin SD, Archer CH, Qian W, Castillo-Badillo J, Yin X, Disbennett WM, Miner A, Holley JA, Naismith T, Stinson WA, Wei X, Ning Y, Fu J, Ochoa TA, Surve N, Zaver S A, Wodzanowski KA, Balka KR, Venkatraman R, Liu C, Rome K, Bailis W, Shiba Y, Cherry S, Shin S, Semenkovich CF, De Nardo D, Yoh S, Roberson EDO, Chanda SK, Kast DJ, and Miner JJ. : ArfGAP2 promotes STING proton channel activity, cytokine transit, and autoinflammation. Cell Feb 2025.

Chauvin SD, Holley JA, Poddar S, Miner CA, Kumble L, Fu J, Laue-Gizzi H, Hardy TA, Miner JJ. : Prime editor gene therapy and TREX1 mosaicism in retinal vasculopathy with cerebral leukoencephalopathy. J Clin Immunol 41(1): 54, Dec 2024.

Chauvin SD, Ando S, Holley JA, Sugie A, Zhao FR, Poddar S, Kato R, Miner CA, Nitta Y, Krishnamurthy SR, Saito R, Ning Y, Hatano Y, Kitahara S, Koide S, Stinson WA, Fu J, Surve N, Kumble L, Qian W, Polishchuk O, Andhey PS, Chiang C, Liu G, Colombeau L, Rodriguez R, Manel N, Kakita A, Artyomov MN, Schultz DC, Coates PT, Roberson EDO, Belkaid Y, Greenberg RA, Cherry S, Gack MU, Hardy T, Onodera O, Kato T, Miner JJ.: Inherited C-terminal TREX1 variants disrupt homology-directed repair to cause senescence and DNA damage phenotypes in Drosophila, mice, and humans. Nature Communications 15(1): 4696, Jun 2024.

Miner JJ, Fitzgerald KA.: A path towards personalized medicine for autoinflammatory and related diseases. Nature Reviews Rheumatol 19(3): 182-189, Mar 2023.

Chauvin SD, Stinson WA, Platt DJ, Poddar S, Miner JJ.: Regulation of cGAS and STING signaling during inflammation and infection. Journal of Biological Chemistry 299(7): 104866, July 2023.

Platt DJ, Lawrence D, Qian W, Rodger R, Schriefer L, Miner CA, Menos AM, Kennedy EA, Peterson ST, Stinson WA, Baldridge MT, Miner, JJ: Transferrable protection by gut microbes against STING-associated lung disease. Cell Rep 35(6): 109133, May 2021.

Bennion BG, Croft CA, Ai TL, Qian W, Menos AM, Miner CA, Fremond ML, Doisne JM, Andhey PS, Platt DJ, Bando JK, Wang ER, Luksch H, Molina TJ, Robison EDO, Artyomov MN, Rosen-Wolff A, Colonna M, Rieux-Laucat F, Di Santo JP, Neven B, Miner JJ. : STING gain-of-function disrupts lymph node organogenesis and innate lymphoid cell development in mice. Cell Rep 31(11): 107771, Jun 2020.

Luksch H, Stinson WA, Platt DJ, Qian W, Kalugotla G, Miner CA, Bennion BG, Gerbaulet A, Rösen-Wolff A, Miner JJ.: STING-associated lung disease in mice relies on T cells but not type I interferon. J Allergy Clin Immunol 144(1): 154-266, Jul 2019.